# Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

> **NCT03896750** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 12 (actual)

## Conditions studied

- Renal Impairment
- Tuberculosis

## Interventions

- **DRUG:** PA-824

## Key facts

- **NCT ID:** NCT03896750
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-17
- **Primary completion:** 2024-08-10
- **Final completion:** 2024-10-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896750, "Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03896750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*